Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune SA (NASDAQ: ACIU) has announced the presentation of its innovative SupraAntigen® liposomal vaccine platform at the upcoming CTAD conference in San Francisco from November 29 to December 2, 2022. The company will present data on its anti-phospho-Tau vaccines, ACI-35 and JACI-35, showcasing their safety and immunogenicity. Key presentations include interim data from a Phase 1b/2a study and insights into biomarkers related to Alzheimer’s disease. This highlights AC Immune's commitment to developing targeted active vaccines for neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company focused on neurodegenerative diseases, will participate in the 2022 Jefferies London Healthcare Conference from November 15-17, 2022. CEO Dr. Andrea Pfeifer will discuss the company's precision medicine approach and its pipeline, aiming for earlier diagnosis and prevention of diseases like Alzheimer’s. Notably, an interim analysis of the Phase 1b/2 ABATE study on the anti-amyloid-beta vaccine ACI-24.060 is among three key clinical readouts expected by year-end. The fireside chat is set for November 15, 2022, at 3:00 AM ET.
AC Immune SA (NASDAQ: ACIU) announced significant advancements in its clinical programs, including the initiation of dosing for the anti-Abeta vaccine ACI-24.060 in the Phase 1b/2 ABATE study targeting prodromal Alzheimer’s disease and Down syndrome patients. The company also received clearance for a Phase 2 study of the anti-alpha-synuclein vaccine ACI-7104 in early Parkinson’s disease patients. With a strong cash position of CHF 140.5 million, AC Immune expects to fund operations into Q3 2024. However, recent Phase 2 study results showed no statistically significant benefits from crenezumab.
AC Immune SA (NASDAQ: ACIU) provided an update on its Phase 1b/2 ABATE study for ACI-24.060, an anti-amyloid-beta vaccine targeting Alzheimer's disease and Down syndrome patients. The trial has received regulatory approval in the UK and Spain, with recruitment underway. A U.S. Investigational New Drug application is planned for Q1 2023. Interim analysis is expected by year-end 2022, which will inform the transition to Phase 2. ACI-24.060 demonstrates high immunogenicity and potential as a best-in-class therapy against Alzheimer's-related amyloid plaques.
AC Immune (NASDAQ: ACIU) announced that its Tau PET tracer, PI-2620, is advancing to late-stage clinical development for Alzheimer's Disease (AD) as confirmed by its partner, Life Molecular Imaging (LMI). AC Immune will receive a milestone payment from LMI. This promising Tau PET tracer shows high binding affinity for aggregated Tau, a key indicator of neurological decline. Phase 2 trial results presented at the Alzheimer's Association International Conference indicated that PI-2620 could accurately detect Tau deposits, aiding in early diagnosis and monitoring of cognitive impairment.
AC Immune (NASDAQ: ACIU) has received a new grant from The Michael J. Fox Foundation (MJFF) to advance its alpha-synuclein PET tracer, ACI-12589, bringing total funding to USD 3.7 million. This support enables enhanced clinical studies, following proof-of-concept data showcasing the tracer's ability to generate live images of alpha-synuclein in the human brain. If successful, ACI-12589 may become a pioneering diagnostic tool for Parkinson’s disease, facilitating the development of new therapies.
AC Immune SA (Nasdaq: ACIU) hosted a webinar featuring Dr. Cynthia A. Lemere discussing the potential of vaccines in treating Alzheimer's and Parkinson's diseases. The session highlighted their precision medicine approach, focusing on three clinical-stage vaccines targeting Tau, Abeta, and α-synuclein. Vaccines are positioned to provide long-lasting immunity and cost-effective treatment options. The company’s pipeline includes ACI-35.030, ACI-24.060, and ACI-7104, with expected clinical data disclosures in 2022, showcasing their commitment to combating neurodegenerative diseases.
AC Immune SA (Nasdaq: ACIU) will host a KOL webinar on August 24, 2022, at 10:00 AM ET, focusing on innovative vaccination strategies for Alzheimer's and Parkinson's diseases. The event will feature Dr. Cynthia A. Lemere from Brigham & Women's Hospital, discussing the immunotherapy landscape and biomarker selection. AC Immune's management will present their precision medicine approach and pipeline. A live Q&A session will follow the presentation. Registration is available online, with a replay planned for later viewing on the company's website.
AC Immune SA (Nasdaq: ACIU) announced the presentation of findings from the Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer’s Disease (ADAD) Colombia Trial at the Alzheimer’s Association International Conference. Crenezumab, the anti-amyloid beta antibody tested, was safe with no ARIA-E cases observed. Numerical differences favoring crenezumab over placebo were noted, but none reached statistical significance. The study's limitations included lower statistical power due to the population's demographics. All mutation carriers will continue receiving crenezumab as data is further analyzed.
AC Immune SA (NASDAQ: ACIU) announced significant clinical advancements and financial updates. The company has delivered three clinical readouts in 2022 and aims for four more by year-end. The first patient has been dosed in the Phase 1b/2 trial of its anti-Abeta vaccine ACI-24.060 targeting Alzheimer's and Down syndrome. Financially, AC Immune holds CHF 154.1 million, ensuring operations through Q1 2024. However, a net loss of CHF 19.6 million was reported for Q2 2022, slightly higher than the previous year's loss.